Download CURRICULM VITAE

CURRICULM VITAE
Name: 張俊彥 (Jang-Yang Chang), M.D.
Date of birth: Jan. 23, 1956
Citizen: Taiwan, R.O.C.
Marital status: married, two daughters
Education:
1982
M.D. National Defense Medical Center, Taipei, Taiwan, R.O.C.
Work Experience:
2008. 09
Distinguished Investigator of National Institute of Cancer
Research, NHRI
2008. 01
Director of National Institute of Cancer Research, NHRI
2007. 08
Attending Physician of Division of hematology/Oncology, NCKUH
Joined Professor of Medical School of National Cheng-Kung
2007.08
University
2006. 01 ~
Deputy Director of National Institute of Cancer Research, NHRI
2004. 06 ~2008
Chairman of Safety and Data Monitoring committee, TCOG
2004. 04 ~
Investigator of NHRI
2003. 08 ~
Adjunct Professor of Internal Medicine, NDMC (部定:教字 013198)
2003 ~ 2005
常務理事, Chinese Oncology Society
2001 ~
Board member of Chinese Oncology Society
2000. 09 ~ 2004. 03
Associate investigator of NHRI
1999 ~
Board member of Sino-American Cancer Foundation
1997-2006
Adjunct Attending physician of Department of Oncology, NTUH
1997 ~
Senior Attending physician of NHRI
1997 ~ 2001
General Secretary of Chinese Oncology Society
1997
Chief of Hematology / Oncology, Cheng-Hsien Medical Center
1994 ~ 2003. 07
Associate Professor of internal medicine, NDMC (部定, 副字
21234)
1994 ~ 1996
Board member of Chinese BMT Society
1993 ~
Chief of Medical Oncology, Tri-Service General Hospital, National
Defense Medical Center
1991 ~ 1992
Attending physician of Medical Mission in Republic of Central
1
17/05/03
Africa
1989 ~ 1991
Visiting Scholar of Yale Medical School, Department of
Pharmacology
1987 ~ 1989
Fellow of Medical Oncology Training Program of Institute of
Biomedical Science, Academia Sinica
1987 ~
Attending Physician of Hematology / Oncology, Tri-Service
General Hospital, NDMC
1986 ~ 1987
Chief resident of Division of Hematology / Oncology, Department
of Internal Medicine, TSGH, NDMC
1982 ~ 1986
Resident of Department of Medicine, TSGH, NDMC
1981 ~ 1982
Internship training, Tri-Service General Hospital
Certification:
1. Board of Internal Medicine, R.O.C.
2. Board of Hematology, R.O.C.
3. Board of Medical Oncology, R.O.C.
Associations:
1. Chinese Association of Internal Medicine
2. Chinese Association of Hematology
3. Chinese Association of Oncology
4. Active member of American Association for Cancer Research
5. Member of Society of Chinese Bioscientists in America
Member of Committee:
1. Executive member of Taiwan Cooperative Oncology Group
2. Member of breast cancer committee, TCOG.
3. Member of prostate cancer committee, TCOG.
4. Member of chemotherapy committee, TCOG.
5. Member of Joint IRB
6. Member of NIRB
7. Consultant of CDE
8. Consultant of National Biotechnology and Pharmaceutical program
Reviewer of peer-reviewed journal:
1. Life Sciences
2. Journal of Formosa Medicine Association
3. Cancer Investigation
4. Journal of Pharmacology and Experimental Therapeutics
5. Asia-Pacific Journal of Clinical Oncology
2
17/05/03
6. Acta Pharmacologica Sinica
7. International Journal of Cancer
8. Bioorganic and Medicinal Chemistry
9. Bioorganic and Medicinal Chemistry Letters
10. Journal of Medicinal Chemistry
11. Cancer Letters
12. Molecular Cancer Therapeutics
Editorial Board Member:
Cancer Letters (2010Grand reviewer:
1. National Science Council, Taiwan, ROC
2. Research Grands Council of Hong Kong, 20023. Italian Cancer research association, 2003
4. Health research Board, Ireland, 2004
Major Research Interests:
1. Development of anticancer drugs
2. Study the mechanisms of anticancer drug resistance.
Research projects:
Clinical studies:
1. A phase III study of postoperative adjuvant chemoradiotherapy for patients with stage III and
IVb stomach cancer. (PI)
2. A phase II study of gemcitabine and vinorelbine in cisplatin-resistant nasopharyngeal
carcinoma patients. (co-PI)
3. A phase I study of PI-88 in advanced malignancies. (co-PI)
4. A phase I and PK study of thalidomide in hepatocellular carcinoma. (co-PI)
5. A phase II study of weekly CPT-11 in recurrent NPC. (PI)
6. A phase II study of weekly oxaliplatin plus HDFL in patients with advanced gastric cancer
(co-PI)
7. A phse II study of taxol, UFT and leucovorin in patients with advanced gastric cancer. (co-PI)
8. A phase I/II study of docetaxel, cisplatin and HDFL in patients with advanced gastric cancer.
(PI)
9. A phase III study of thalidomide in patients with poor liver function hepatocellular carcinoma.
(co-PI)
10. Phase I and PK studies of PEP02 in patients with advanced malignancies. (PI)
11. Phase I study of PEP02 with HDFL in patients with advanced malignancies. (co-PI)
12. Phase I and PK study of biweekly PEP02 in patients with advanced colorectal cancer (PI).
3
17/05/03
Basic studies:
1. Study the distribution of somatostatin receptor in human cancer tissue.
2. Study the mechanism of CPT resistance in human nasopharyngeal cancer cells.
3. Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological
evaluation.
4. Synthesis and structure-activity relationships of new AHMA derivatives as topoisomerase-II
mediated antitumor agents.
5. Study the indole derivatives as antitumor agents.
6. Study the mechanims of action of BPR0Y007, a novel anticancer agent.
7. Study the role of O6-MGMT in determining the cytotoxicty of topoisomerase I inhibitors.
8. Transcriptional inhibition of O6MGMT gene of topoisomerase I inhibitors.
9. Isolation the putative transporter responsible for resistance to topoisomerase I inhibitors in a
vincristine-resistant cell line.
10. Study the mechanism of action of a potential antitumor agent isolated from a herb medicine.
11. Study the interaction of arsenic trioxide with antitumor agents.
12. Study the interaction of new topoisomerase I inhibitor, DB67, with other antitumor agents.
13. Study the pathway of BPR0Y007-induced apoptosis.
14. Study on the regulation of DNA repair enzyme, MGMT, in human cancer cells.
15. Study on the development of anti-tubulin compounds
Award:
1. Outstanding Poster award, The 6th Annual Taiwan Joint Cancer Conference, 2001
2. Outstanding Poster award, The 8th Annual Taiwan Joint Cancer Conference, 2003
3. Outstanding Poster award, The 9th Annual Taiwan Joint Cancer Conference, 2004
4. 徐千田防癌研究基金癌症傑出研究獎 (基礎組), 2005
5.
6.
7.
8.
9.
Outstanding Poster Award, The 10th Annual Taiwan Joint Cancer Conference, 2005
Outstanding Poster Award, The 11th Annual Taiwan Joint Cancer Conference, 2006
Outstanding Poster Award, The 12nd Annual Taiwan Joint Cancer Conference, 2007
Outstanding Poster Award, The 13rd Annual Taiwan Joint Cancer Conference, 2008
Outstanding Poster Award, The 15th Annual Taiwan Joint Cancer Conference, 2010
Publications:
(A) Research Articles
1. Lin JS, Yu KP, Hwang WS, Lee WC and Chang JY. Chronic myelocytic
leukemia—Clinical analysis of 52 cases. Chin Med J 36:372-378, 1985
4
17/05/03
2. Hwang WH, Lee EC and Chang JY. Epirubicin in combination chemotherapy for
3.
4.
5.
6.
hematological malignancy. J Med Sci 8 (1): 1987
Chang JY, Hwang WS, Yu KP and Lee WC, Combination chemotherapy of Non-Hodgkin’s
Lymphoma with CHOP. J Med Sci 8 (4) , 1988
Cheng AL, Chen YC, Wang CW, Tien HF, Chang JY, Hwang WS, Su WC and Liu CH.
Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of
comparable histological grades-Should peripheral T-cell lymphoma be considered separately?
J Clin Oncol 7 (6): 725-731, 1989
Chang JY, Hwang WS and Lee WC, Superior vena caral syndrome. (in Chinese), Medical
Digest 8 (3): 226-228, 1989
Lee KH, Beers SA, Mori M, Wang ZQ, Li Li, Liu SY, Chang JY, Han FS and Cheng YC.
Antitumor agents 111. New 4’-hydroxylated and 4’-halogenated anilino derivatives of
4’-demethylepipodophyllotoxin as potent inhibitor of human DNA topoisomerase Ⅱ. J Med
Chem 33 (5): 1365-1368, 1990
7. Ko WS, Chen A, Yu KP, Chang JY, Hwang WS and Lee WC, Stimultaneous Occurrence of
malignant lymphoma and hepatocellular carcinoma. Hemal Soc Aut 15-18, 1990
8. Wang ZQ, Kuo YH, Schnur D, Bwoen JP, Liu SY, Han Fs, Chang JY, Cheng YC and Lee
KH,
Antitumor
agents
113.
New
4B-arylamino
derivatives
of
4’-o-demethylepipodophyllotoxin and related compounds as potent inhibitors of human
DNA topoisomeraseⅡ. J Med Chem 33 (9): 2661-2666, 1990
9. Chang JY, Han FS, Liu SY, Wang ZQ, Lee KH and Cheng YC. Effect of 4B-arylamino
derivatives of 4’-o-demethylepipodophyllotoxin on human DNA topoisomeraseⅡ, tubulin
polymerization, KB cells and their resistant variants. Cancer Res. 51: 1755-1759, 1991
10. Emily O, Ngo, Sun TP, Chang JY, Wang CC, Chi KH, Cheng AL and Nutter LM,
Menadione-induced DNA damage in a human tumor cell line. Biochem Pharmacol 42 (10):
1961-1968, 1991
11. Chang JY, Chen LM, Tseng HW and Hwang WS. Granulocytic sarcoma with massive skin
involvement. Hemal Soc Aut. 71-77, 1991
12. Chang JY, Dethlefsen LY, Barley LR, Zhou BS and Cheng YC, Characterization of
camptothecin-resistant Chinese hamster lung cells. Biochem Pharmacol 43 (11): 2443-2452,
1992
13. Wang ZQ, Shen YC, Chen HX, Chang JY, Guo X, Cheng YC and Lee KH. Antitumor
agnets
126.
Novel
4B-substituted
anilino
derivatives
of
3’4’-O’O’
didemethylpodophyllotoxin as potent inhibitors of human DNA topoisomerase Ⅱ.
Pharmaceutical Res. 10 (3): 343-350, 1993
14. Huang SH, Chang JY, Hsueh EJ, Sheu LF and Hwang WS. Lymphoblastic lymphoma in
adult: an experience of 15 cases treated at the Tri-Service General Hospital. J Med Sci 14:
193-200, 1993
15. Chang JY and Hwang WS. Disseminated Intravascular Coagulation. Med Digest 6 (17):
504-508, 1993
5
17/05/03
16. Wang WS, Yang YF, Chang JS and Chang JY. A comparison study of regular
metoclopramide with long-acting metoclorpamide for prophylaxis chemotherapy-induced
delayed nausea and vomiting in patients with gynecological cancer. J Obstet and Gynecol
ROC 32 (4): 1-5, 1993
17. Harn HJ, Chang JY, Wang MW, Ho LI, Lee HS, Chiang JH, Lee WH. Epstein-Barr
Virus-associated Gastric Adenocarcinoma in Taiwan. Human Path, 26 (3): 267-271, 1995
18. Harn HJ, Ho LH, Chang JY, Wu CW, Wang MW, Jiang SY, Lee HS, Lee WH.
Differentiation expression of human metastasis adhesion molecule CD44V I Chinese
stomach carcinoma. Cancer 75 (5): 1065-1071, 1995
19. Yu FC, Chang JY*, Hwang SH, Lee HS and Hwang WS. Kappa light chain multiple
myeloma with myelomatous pleural effusion-a case report and review of literature. J Med
Sci 15 (1): 49-56, 1994
20. Juan MT, Sheu LF, Chang JY* and Hwang WS. Primary Non-Hodgkin’s lymphoma of the
Mediastinum: A Clinicopathological Report of Six cases. Chin Med J (Taipei) 55: 325-330,
1995
21. Chao TY, Ting CS, Yeh MY, Chang JY, Wang CC and Chu TM. Effects of indomethacin on
lymphokine-activated killer cell activitives in cancer patients. Tumor Biol 16: 230-242, 1995
22. Gao GW, Huang SH and Chang JY. Vertebral metastasis with spinal cord compression as
an initial presentation of rare hepatocellular carcinoma. J Med Sci 16 (1): 68-73, 1995
23. Chao TY, Chang JY, Ju CY and Tsao TY. Diagnosis of disseminated candidiasis by fine
needle aspiration of lymph node and by splenetic imprint in a patient with acute
promyelocytic leukemia. Acta Haematol 1995; 94: 148-151
24. Huang SH, Ger LP, Hsueh EJ, Cheng LM and Chang JY. A randomized comparative trial
of ordansetron versus metoclorpomide-based combination regimen in the prevention of
cisplatin-induced emesis. J Med Sci 16(2):108-114, 1995
25. Chen YC, Chao TY, Hsueh EJ, Huang SH, Wang CC and Chang JY (corresponding author).
A randomized study comparing tropisetron with combined metoclopromide and
dexamethasone in the prevention of cisplatin-induced emesis. J Chniese Oncol. Soc. 11
(2):1-8, 1995
26. Biedler DR, Chang JY, Zhou BS and Cheng YC. Camptothecin resistance involving steps
subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant
KB cell lines. Cancer Res, 56: 345-353, 1996
27. Harn HJ, Ho LI, Liu CA, Lin FG, Lin JJ, Chang JY, Lee WH. Down regulation of bcl-2 by
p53 in nasopharyngeal carcinoma and lack of detection of its specific t(14;18) chromosomal
translocation in fixed tissues. Histopathology, 28(4): 317-23, 1996
28. Hsueh EJ, Hwang WS, Huang SH, Chao TY, Chang JY, Wang CC. Allogeneic Bone
Marrow Transplantation for fourteen patients with severe Aplastic Anemia. China Med J
(Taipei) 1996; 57: 247-253
29. Chao TY, Chow KC, Chang JY, Wang CC, Tsao TY, Harn HY, Chi KH Expression of
Epstein-Barr Virus-Encoded RNAs as a marker for metastastic undifferentiated
6
17/05/03
Nasopharyngeal Carcinoma. Cancer. July: 24-29 1996
30. Chen Li-Mien, Chao TY, Chiang JH, Chang JY, Hwang HS, Hseuh EJ, Wang CC.
Examination of pericardial effusions by cytology and immunocytochemistry. Chin Med J
(Taipei). 1996, 58 (4): 248-253
31. Yang Ching-Yue, Wong CS, Chang JY, Ho ST. Intrathecal ketamine reduces morphine
requirements in patients with terminal cancer patients. Can J Anaesth 43; 4: 379-83, 1996
32. Huang WH, Hseuh EJ, Huang SH, Chao TY, Wang CC and Chang JY. The effects of
human granulocyte colony stimulating factor in allogenic bone marrow
transplantation—TSGH experience. Journal of Medical Science 1996; 16: 349-354
33. Hwang WS, Hsiung CA, Ko WS, Wang CC, Chang JY, Lai GM, Hsieh RK, Tsao CJ, Chen
LT, Law CK, Cheng AL, Fan SF, Tzeng CH, Chiou TJ, Whang-Peng J. Weekly CAF
Chemotherapy for Advanced Breast Cancer Patients. Oncology 1997; 54: 293-297
34. Chen YC, Chang JY, Hsuch EJ, Wan HL, Chao TY. Acquired Hemophilia A: report of two
cases. Chin Med J ( Taipei) 1998:538-544
35. 張俊彥*. 癌症治療的新進展。當代醫學雜誌 531-538,1999
36. 張俊彥* 與第一型拓樸脢有關的抗癌藥物的新進展。國防醫學，30(2): 124-128, 2000
37. Chang JY, Guo X, Chen HX, Wang HK, Bastow KF, Zhu XK, Guan J, Lee KH, Cheng YC.
Unique Biochemical, Cytotoxicity and Antitumor Activity of Camptothecin and
4-amino-4’-O-demethyl Epipodophyllotoxin Conjugates, Biochemical Pharmacology.
59:497-508, 2000
38. Liu JM, Chen LT, Chao Y, Wu CW, Wu HW, Lee KD, Chang JY, Whang-peng J. Phase II
and pharmacokinetic study of GL331 in refractory gastric cancer patients. Cancer Chemo
and Pharmacol. 49: 425-428, 2002
39. Chen LT, Liu TW, Wu Cw, Chung TR, Shiah HS, Jan CM, Liu JM, Whang-Peng J and
Chang JY* A Phase I Study of Weekly Docetaxel, Cisplatin Plus 24-Hour Infusion of High
Dose Fluorouracil and Leucovorin in Patients with Advanced Gastric Cancer. Oncology,
63(3): 239-47, 2002.
40. Chang JY*, Liu JF, Jung SH, Liu TW and Chen LT. Novel mutation of topoisomerase I in
rendering cells resistant to camptothecin. Cancer Res. 62: 3716-3721, 2002.
41. Lee KD, Liu TW, Wu CW, Liu JM, Chung TR, Chang JY, Whang-Peng J and Chen LT.
Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated
by peritoneal carcinomatosis-Percutaneous transhepatic duodenal drainage followed by
24-hour infusion of high-dose fluorouracil and leucovorin. Annals of Oncology 13:
1151-1155, 2002
42. Rastogi K#, Chang JY#, Pan WY, Chen CH, Chou TC, Li-Tzong Chen, and Su TL .
Antitumor AHMA Linked to DNA Minor Groove Binding Agents: Synthesis and Biological
Evaluation. J Med Chem., 26: 45(20): 4485-93, 2002 (#contributed equally)
43. Kuo CC, Chaing W, Liu GP, Chen YL, Chang JY, Lee CK, Lo JM, Huang SL, Shih MC
and Kuo YH. 2,2’-diphenyl-1-picrylhydrazyl radical-scavenging active components from
Adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) Hulls. J Agric. Food Chem., 9: 50(21):
7
17/05/03
5850-5855, 2002.
44. Hsieh HP, Liou JP, Lin YT, Marhindroo N, Chang JY, Yang YN, Chen SS, Tan UK, Chang
CW, Chen TW, Lin CH, Chang YY and Wang CC. X-ray crystallographic and molecular
modeling studies of benzophenone derivatives- the potential antimitotic agents. Bioorganic
Medicinal Chemistry Letter, 12: 101-105, 2002
45. Chang JY*, Hsieh HP, Pan WY, Liou JP, Bey SJ, Chen LT, Liu JF and Song JS, Dual
Inhibition of Topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic
agent. Biochemical Pharmacology 65(12): 2009-2019, 2003.
46. Chang JY, Lin CF, Pan WY, Bacherikov V, Chou TC, Chen CH, Dong H, Cheng SY, Tsai
TJ, Lin YW, Chen KT, Chen LT and Su TL. New analogues of AHMA as a potential
antitumor agents: synthesis and biological activity. Bioorganic and Medicinal Chemistry 11:
4959-4969, 2003
47. Chang JY*, Chang CY, Kuo CC, Chen LT, Wein YS and Kuo YH. Salvinal, a novel
microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Dansen), with antimitotic
activity in multidrug-sensitive and –resistant human tumor cells. Molecular Pharmacology
65(1): 77-84, 2004
48. Chang Chi-I, Kuo CC, Chang JY and Kuo YH. Three new oleanane-type triterpenes from
Ludwigia octovalvis with cytotoxic activity against human cancer cells. J. Nat. Prod. 67,
91-93, 2004
49. Liou JP#, Chang JY#, Chang CW, Liu YC, Chang CY and Hsieh HP. Synthesis and
structure-activity relationship of 3-aminobenzophenones as antimitotic agents. J Med.
Chemistry, 2897-2905, 2004. (#contribute equally).
50. Juang SH, Pan WY, Kuo CC, Liou JP, Chen LT, Hsieh HP and Chang JY*. A novel
bis-benzylidenecyclopentanone derivative, BPR0Y007, inducing a rapid caspase activation
involving upregulation of Fas (CD95/APO-1) and wild-type p53 in human oral epidermoid
carcinoma cells. Biochemical Pharmacology. 68(2): 293-303, 2004 (corresponding author).
51. Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu MF, Chang CS, Chang JY, Chung CY,
Kao WY, Hsieh RK and Cheng AL. Phase II study of weekly oxaliplatin and 24-hour
infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric
cancer. British Journal of Cancer, 91(3): 453-8, 2004
52. Kuo, CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT and
Chang JY*. BPR0L075, a novel synthetic indole compound with antimitotic activity in
human cancer cells, exerts effective antitumoral activity in vivo. Cancer Research, 64:
4621-4628, 2004
53. Liou JP, Chang YL, Kuo FM, Chang CW, Tseng HY, Wang CC, Yang YN, Chang JY, Lee
SJ, Hsieh HP. Concise Synthesis and Structure-Activity Relationships of Combretastatin A-4
Analogues, 1-Aroylindoles and 3-Aroylindoles, as Novel Classes of Potent Antitubulin
Agents. J Med. Chem. 47, 4247-4257, 2004
54. Chang JY, Ka WS, Chao TY, Liu TW, Chuang TR and Chen LT. Treatment of
hepatocellular carcinoma with intra-atrial tumor thrombi- a report of three
8
17/05/03
thalidomide-responsive cases and literature review. Oncology 67: 320-326, 2004
55. Chang JY*. Discovery of novel microtubule inhibitors as potential anticancer agent.
Journal of Chinese Cancer Society (review), 21 (2): 1-9, 2005
56. Chang CI, Chang JY, Kuo CC, Pan WY and Kuo YH. Four New
6-Nor-5(67)abeoabietane Type Diterpenes and Antitumoral Cytotoxic Diterpene
Constituents from the Bark of Taiwania cryptomerioides. Planta Medica, 71(1):
72-76,2005
57. Chiang YM, Chang JY, Kuo CC, Chang CY and Kuo YH. Cytotoxic triterpines from the
aerial roots of Ficus Mircocarpa. Phycochemistry, 66 (4): 495-501, 2005
58. Chen CC, Chang JY, Liu KJ, Chan CH, Ho JH, Lee SC, and Chen LT. Hepatocellular
carcinoma associated with acquired von Willebrand disease and extreme thrombocytosis.
Annals of Oncology (Letter), 16(6), 988-9, 2005
59. Chan CH, Liu TW, Chen LT, Chang JY and Whang-Peng J. Long term complete remission
of metastatic gastric cancer after weekly docetaxel. 24-hour infusion of high dose 5-FU and
cisplatin. J Gastroenterology and Hepatology (Letter), 1470-1, 2005
60. Chen LT, Liu TW, Chang JY, Chao Y, Cheng, AL, Hsu C, Liu JM, Chuang TR, Chin YH,
Wu CY, and Whang-Peng J. Clinical Significance of alpha-fetoprotein Response in
Thalidomide-treated Advanced Hepatocellular Carcinoma. Alimentary Pharmacology and
Therapeutics 22 (3): 217-226, 2005
61. Wang CC, Chang JY, Liu TW, Lin JY, Hsu CH, Yang CH, Yu YJ and Hong RL. Phase II
study of gemcitabine/vinorelbine (GV) in the treatment of cisplatin-resistant nasopharyngeal
carcinoma (NPC)—Head Neck, 28(1) 74-80, 2005
62. Bacherikov VA, Chang JY, Lin YW, Chen CH, Pan WY, Dong H, Lee RZ, Chou TC, and
Su TL. Synthesis and antitumor activity of 5-(9-acrydinylamino)anisitine derivatives.
Bioorganic and Med. Chem. 13: 6513-6520, 2005
63. Shiah HS, Liu TW, Chen LT, Chang JY. Liu JM, Chuang TR, Lee WS and Wnang-Peng J.
Pulmonary embolism after transcatheter arterial chemoembolizaton Eur. J Cancer Care
14(5): 440-2, 2005
64. Kuo CC, Liu JF and Chang JY*. DNA repair enzyme,O6-methylguanine methyltransferase,
modulates the cytotoxicity of CPT-derived topoisomerase I inhibitors. Journal of
Pharmacology and Experimental Therapeutics 316(2): 946-954, 2006 (NSC
94-2752-B-400-001-PAE)
65. Shiah HS, Chen LT, Chao Y, Yao TJ, Huang JD, Chang JY, Chen PJ, Chuang TR, Chin YH,
Jacqueline Whang-Peng, Liu TW. Phase I and Pharmacokinetic Study of Oral Thalidomide
in Advanced Hepatocellular Carcinoma. Cancer Chemotherapy and Pharmacology 21(3):
531-6, 2006
66. Shiah HS, Chen AL, Hsu C, Hsu CH, Liu TW, Chang JY, Jan CM, Chao Y, Yu WL, Chuang
TR, Whang P and Chen LT. Phase I-II study of gemcitabine and high dose 5-FU and
leucovorin in advanced pancreatic cancer. J Gastroenterology and Hepatology, 21(3): 531-6,
2006
9
17/05/03
67. Ch’ang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin JT, Wang HP, Liu TW,
Chang JY, Whang-Peng J and Chen LT. Phase I study of biweekly gemcitabine followed by
oxaliplatin and simplified 48-hr infusion of 5-fluorouracil/leucovorin for advanced
pancreatic cancer. J Gastroenterology and Hepatology, 21(5): 874-9, 2006
68. Chen YL#, Lin SZ#, Chang JY#, Cheng YC, Tsai NM, Chang WL and Harn HJ. A novel
potential anticancer agent of usochaihulactone on human lung cancer A549 in vitro and in
vivo study. Biochemical Pharmacology 28: 72(3): 308-319, 2006 (#contributed equally)
69. Liou JP, Mahindroo N, Kuo, FM, Lee SWH, Yeh TK, Tan UK, Kuo CC, Chang YW, Lu PH,
Tung YS, Lin KT, Chang JY* and Hsieh HP*. SAR Studies of 3-Aroylindoles as Potent
Antimitotic Agents to Improve the Physicochemical Properties. ChemMedChem, 1:
1106-1118, 2006 Sep 1 (NSC 94-2113M-400-001)
70. Chang JY, Yang MF, Chang CY, Chen CM, Kuo CC and Liou JP*. 2-amino and
2’-aminocombrestatins as potent antitubulin agents. J Med Chem 49: 6412-6415, 2006
(NSC 95-2752-B-400-001-PAE; NSC 94-2323-B-038-005)
71. Bacherikov VA, Tsai TJ, Chang JY, Chou TC, Leu RZ and Su TS. Synthesis of new
camptothecin analogues in E-L lactone ring replaced with α, β-cyclohexenone. Eur J Org
Chem 4490-4449, 2006
72. Chang JY, Hsieh HP, Chang CY, Hsu KS, Chiang YF, Chen CM, Kuo CC and Liou JP*.
7-Aroyl-aminoidoline-1-sulfonamides as a novel class of antitubulin agents. J Med Chem
49:6656-6659, 2006 (NSC 95-2752-B-400-001-PAE; NSC 95-2320-B-038-008)
73. Tse SK, Chang JY, Su WL, Chow SC, Hsiung C and Lu Q. Statistical Quality Control
Process for Traditional Chinese Medicine. J Biopharm Stat. 2006;16(6):861-74.
74. Hsieh CL, Tseng MH, Shao YY, Chang JY, Kuo CC, Chang CY and Kuo YH. C35
terpenoids from the bark of Calocedrus macrolepis var. formosana with cytotoxic activity
against human cancer cell line. J Nat Prod 27;69(11):1611-1613, 2006
75. Mahindroo N, Liou JP, Chang JY*, Hsieh HP* Antitubulin agents for treatment of cancer- A
medicinal chemistry update. Experts Opinion on Therapeutic Patents (Invited review)
16(5): 643-691, 2006 SCI:1.488
76. Juang SH, Lung CC, Hsu PF, Hseu KS, Li YC, Hong PC, Shiah HS, Kuo CC, Huang CW,
Wang YC, Huang LY, Chen TS , Fong Chen SF, Fu KC , HL Hsu, Lin MJ, Chang CJ, Chou
KM, and Chang JY*. D-501036, a Novel Selenophene-based Triheterocycle Derivative,
Exhibits Potent in vitro and in vivo Anti-tumoral Activity Which Involves DNA damage and
ATM activation. Molecular Cancer Therapeutics 6: 193-202, 2007 (NSC
94-2752-B-400-001-PAE)
77. Shiah HS, Lee WH, Juang SH, Chang CJ, Chou KM and Chang JY*.
Mitochondria-mediated and p53-associated apoptosis induced in human cancer cells by a
novel selenophene derivative, D-501036. Biochemical Pharmacology 73(5): 610-619,
2007(NSC 94-2752-B-400-001-PAE)
78. Chang WSW, Wu HR, Yeh CT, Wu CW and Chang JY. Lysosomal cysteine proteinase
cathepsin S as potential target for anti-cancer therapy J. Cancer Mole. 3(1): 5-14, 2007
10
17/05/03
79. Chang WSW*, Chou RH, Wu CW and Chang JY* Human tissue kallikreins as diagnostic
biomarkers and as targets for anticancer therapy. Experts Opinion on Therapeutic Patents
17(10): 1227-1240, 2007 (Invited review)
80. Chien SC, Chang JY, Kuo CC, Hsieh CC, Yang NS and Kuo YS. Two novel skeleton
compounds, chamaecypanone C and obtunorligan A, from the heartwood of Chaelaecyparis
obtuse var.formosana. Tetrahedron Letters. 48(6); 1567-1569, 2007
81. Chen CC, Chen LT, Tsou TC, Pan WY, Yeh SC, Tsai FY, Hsieh HP and Chang JY*.
Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line
with enhanced sensitivity to 5-fluorouracil. British Journal of Cancer 97(3): 334-344, 2007
(NSC 95-2752-B-400-001-PAE)
82. Liou JP, Wu CY, Chang CY, Chen CM, Kuo CC and Chang JY*. 4- and 5- aroylindoles as
novel classes of potent antitubulin agents. J Med Chem 50:4548-4552, 2007 (NSC
95-2752-B-400-001-PAE; NSC 95-2320-B-038-008)
83. Kuo CC, Liu JF, Shiah HS, Ma, LC and Chang JY*. Tamoxifen accelerates proteosomal
degradation of O6-methylguanine DNA methyltransferase in human cancer cells.
International Journal of Cancer, 121(10):2293-300, 2007 Jun 27; [Epub ahead of print]
(NSC 95-2752-B-400-001-PAE)
84. Liou JP, Hsu KS, Kuo CC, Chang CY and Chang JY*. A novel oral indoline-sulfonamide
agent, J30, exhibits potent activity against human cancer cells in vitro and in vivo through
the disruption of microtubule. JPET, Oct;323(1):398-405, 2007 Jul 27; [Epub ahead of print]
(NSC 95-2752-B-400-001-PAE)
85. Kao YH, Hsieh HP, Chitlimalla SK, Kuo CC, Hsu KS, Chang CY, Liu CF, Tsu YC, Chuang
SE and Chang JY* BPR1H0101, a novel synthetic indole-based peroxisome
proliferators-activated receptor /
ase II catalytic activity.
Anti-Cancer Drugs Feb;19(2):151-158, 2008 (NSC 95-2752-B-400-001-PAE) SCI:2.245
86. Ma LC, Kuo CC, Liu JF, Chen LT and Chang JY*. Transcriptional repression of
O6-methylguanine methytransferase gene
rendering cells
hypersentitive to
N,N’-BIS(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells. Mol. Pharm. 74(2):
517-26, 2008 (Fastforward online publication, May 20, 2008)
87. Liou JP, Wu CY, Kuo CC, Chang CY, Chen CM, Hsieh SP* and Chang JY*. Discovery of
4-amino- and 4-hydroxy-1-aroyindoles as potent tubulin polymerization inhibitors. J Med
Chem, 24; 51(14): 4351-4355, 2008
88. Chen YW, Cleaver J, Hatabet Z, Honkanen R, Chang JY, Yen Y and Chou KM. Human
Polymerase η (eta) activity and translocation is regulated by phosphorylation. PNAS, 105
(43): 16578-83, 2008. [Epub ahead of print]
89. Reddy GR, Kuo CC, Tan UK, Coumar MS, Chang CY, Chiang YM, Lai MC, Wu SY,
Chang JY, Liu JP and Hsieh HP. Synthesis and structure-activity relationships of 2-aminoand 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents. J Med Chem. 2008 25;
51(24): 8163-8167
90. Chang KY, Chang JY, Chao J and Yen Y. Modern staging and utility of PET imaging in
11
17/05/03
esophageal cancer management. J Natl Compr Canc Netw. 2008 Oct; 6(9):862-9.
91. Mohane HC, Cheung CHA, Chang JY and Hsieh HP*. Advances in aurora kinase inhibitors
patents. Experts Opinion on Therapeutic Patents 19 (3): 321-356, 2009 (Invited Review)
92. Lai MJ, Kuo CC, Yeh TK, Hsieh HP, Pan WY, Hsu KY, Chang JY*,and Liou JP*.
Discovery of 1-Benzyl-4,5,6-Trimethoxyindoles as a Novel Class of Potent Antimitotic
Agents. ChemmedChem, Apr;4(4):588-93, 2009
93. Cheung CHA, Coumar MC, Hsieh HP* and Chang JY*. Aurora kinase inhibitors in
preclinical/clinical testing. Experts Opinion on Investigation Drugs, 18 (4): 379-398, 2009
(Invited Review)
94. Chang KY, Chang JY and Yen Y. Increasing incidence of intrahepatic cholangiocarcinoma
and its relationship to chronic viral hepatitis.- JNCCN, 7(4):423-7, 2009
95. Chaing YK, Kuo CC, Chen CT, Coumar MS, Hsieh HP, Chang CY, Jseng HY, Wu MH, Wu
JS, Leou JS, Song JS, Chang JY, Lyu PC, Chao YS and Wu SY. Generation of ligand-based
pharmacophore model and virtual screening for identification of novel anti-tubulin
inhibitors with potent anticancer activity. J Med Chem. 52(14): 4221-33, 2009
96. Chen LT, Shiah HS, Chao Y, Chang JY, Chen LT and Whang-Peng J. Alpha-fetoprotein
response in advanced HCC receiving cytostatic treatment. JCO, 2009 Dec 20;27(36):e271
97. Wu YS#, Coumar MS#, Chang JY#, Sun HY, Kuo FM, Kuo CC, Chen YJ, Chen CY, Liao
JY, Chen CP, Yao HT, Chiang YK, Tau UK, Chen CT, Wu SY, Yeh TK and Hsieh HP.
Synthesize and evaluation of 3-aroulindoles as anticancer agent: metabolic approach. J Med
Chem. 4941-4945, 2009.(# equal contribution)
98. Cheung CHA, Chen HH, Kuo CC, Chang CY, Coumar MS, Hsieh HP and Chang JY*.
Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing
tubulin polymers. Molecular Cancer 8 (1): 43, 2009
99. TK Yeh, CM Li, CP Chen, CL Huang, HS Wang, CJ Shen, CY Chang, CM Chang, YS Chao,
CT Lin, Chang JY*, and CT Chen*. Comparative Antitumor Activities and
Pharmacokinetics of Silatecans DB-67 and DB-91. Pharmacological Research, 61: 108-115,
2010.
100. Hsieh CC, Kuo YH, Kuo CC, Chen LT, Cheung AC, Chao TY, Lin CH, Chang CY, Pan WY,
Chen SC, Chen TW, Lung CC and Chang JY*. Chamacypanone C, a novel skeleton
microtubule inhibitor, with anticancer activity by trigger caspase 8-Fas/FasL dependent
apoptotic pathway in human cancer cells. Biochemical Pharmacology, 79: 1261-1271, 2010.
101. Nien CY, Chen YC, Kuo CC, Hsieh HP, Chang CY, Hsu KY, Liou JP* and
Chang JY*. 5-amino-2-aroylquinolones as highly potent tubulin polymerization inhibitors.
J Med Chem, 11(315): 2309-13, 2010
102. Kanwar RK, Cheung CHA, Chang JY and Jagat R. Kanwar. Recent advances in
anti-survivin treatment for cancer. Current Medicinal Chemistry. 17(15): 1509-15, 2010
103. Arecoline arrests cells at prometaphase by deregulating mitotic spindle
assembly and spindle assembly checkpoint: implication for carcinogenesis
Wang YU, Tsai YS, Huang JL, Ka-Wo Lee KW, Kuo CC, Wang CS, A-Mei
12
17/05/03
Huang AM, Chang JY, Jong YJ, and Chang-Shen Lin CS. Oral Oncology, 46(4): 255-262,
2010
104. Cheung CHA, Chen HH, Cheng LT, Lyu KW, Kanwar JR and Chang JY*.
Targeting Hsp90 with small molecule inhibitors induces the over-expression of
the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29
cancer cells. Molecular Cancer, 15: 9(1): 77, 2010.
105. Chang JY, Lai, MJ, Chang YT, Lee HY, Chen YC, Kuo CC, Su MC, Chang CY
and Liu JP. Synthesis and biological evaluation of
7-arylindoline-1-benzenesulphonamides as a novel class of potent anticancer
agents. MedChemComm 2010 (accepted)
106. Chen JC, Uang BJ, Lyu PC, Chang JY, Liu KJ, Kuo CC, Hsieh HP, Wang HC,
Cheng CS, Chang YH, Chang MTD, Chang WHW, and Chun-Cheng Lin. Design and
synthesize of α-ketoamides as cathepsin S inhibitors with potential applications against tumor
invasion and angiogenesis. J Med Chem, 53(11): 4545-9, 2010
107. Chen CC, Wu JH., Yang NS, Chang, JY, Kuo CC., Wang SY., Kuo YH.* A Cytotoxic C35
Terpenoid Cryptotrione from the Bark of Cryptomeria japonica. Organic Letters 12(12):
2785-2789, 2010 (SCI; Category: Chemistry, Organic; Impact factor: 5.128; Ranking: 4/55,
7.3%, 2008 JCR)
108. Wu YY, Chang JY and Chao TY. Paclitaxel and carboplatin-induced complete remission in
patients with peritoneal carcinomatosis of unknown origin: a report of two cases and review of
literature. Tumori. 96(2): 336-9, 2010
109. Cheung CHA, Cheng LT, Chang KY, Chen HH and Chang JY*. Investigations of the
inhibitor-of-apoptosis protein (IAP), Survivin: the past, present and future. Frontiers in
Bioscience, 2010 (accepted).
110. Lung JH, Liu KJ, Chang JY, Leu SS and Shih NY. MBP-1 is efficiently encoded by an
alternative transcript of ENO-1 gene but post-translationally regulated by
proteosome-dependent protein turnover. FEBS J, 2010 (accepted)
(C) Conference Abstracts
1. Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu, MF, Chang CS, Chang JY, Chung CY,
Kao WY, Hsieh RK, Chang AL. A phase II study of oxaliplatin and weekly 24-hour infusion
of high dose 5-FU and leucovorin in the first line treatment of inoperable, locally advanced
2.
3.
4.
5.
or recurrent/metastatic gastric cancers. Proceeding ASCO, 2002.
Chang JY, Liu JF, Liu TW and Chen LT. Novel mutation of topoisomerase I in rendering
cells resistant to camptothecin. Cross-strait oncology meeting, 2002.
Chang JY, Hsieh HP, pan WY and Liou JP. Dual actions of a new anticancer agent,
BPR0Y007, on DNA topoisomerase I and tubulin. Proceeding AACR , 2002.
Su TL, Rastogi K, Chang JY, Chou TH, Pan WY and Chen LT. AHMA derivatives linked to
DNA minor groove binder as potential antitumor agents. Proceeding AACR, 2002.
Wang CC, Hong RL, Hsu CH, Yang CH, Yu YC and Chang JY. A phase II trial of
gemcitabine/vinorelbine combination in the treatment of platinum-resistant nasopharyngeal
13
17/05/03
carcinoma. Proceeding ASCO, 2003.
6. Kuo CC, Liu JF and Chang JY. O6-methylguanine methyltransferase plays a role in
determining cytotoxicity of topoisomerase I inhibitors. Proceeding AACR , 2003.
7. Kuo CC, Hsieh HP, Pan WY, Chen LT and Chang JY. BPR0L075, an indole analogue with
antimitotic activity in multidrug-sensitive and –resistant human cancer cells. Chinese
Oncology Society Annual meeting, 2003.
8. Chang JY, Lin CF, Pan WY, Chou TC, Chen LT, and Su TL. Synthesis and
Structure-Activity Relationships of New AHMA Derivatives as Topoisomerase II-mediated
antitumor Agents. Chinese Oncology Society Annual meeting, 2003.
9. Kuo CC, Hiesh HP, Pan WY, Liu JP, Chen LT, Chen CT and Chang JY. BPR0L075, a novel
synthetic indole compound with antimitotic activity in multidrug-sensitive and –resistant
cells, exerts effective antitumoral activity in vivo. Proceeding AACR 45:1254, 2004.
10. Jung SH, Pan WY, Kuo CC, Liou JP, Chen LT, Hiesh HP and Chang JY. A novel
bis-benzylidenecyclopentanone derivative, BPR0Y007, inducing a rapid caspase activation
involving upregulation of Fas (CD95/APO-1) and wild-type p53 in human oral epidermoid
carcinoma cells. Proceeding AACR, 45:1057, 2004.
11. Lung CC, Kuo CC, Liu JF, J Whang-Peng and Chang JY. Transcriptional suppression of
MGMT gene in CPT-resistant cells Proceeding AACR: 45:518, 2004.
12. Chen T, Juang SH, Li Y, Huang C, Hsu P, Chen S, Chang JY, Hong P, Hsieh W, Chang
C.Rapid activation of caspases involving microtubule stabilization and p53 upregulation by
D501036, a novel selenophene derivative active against renal cancer cells. Proceeding of
EORTC-NCI-AACR, 235, 2004.
13. Lung CC, Chang CY, Hsu KS and Chang JY. ATP-independent transporter responsible for
the resistance of topoisomerase I inhibitors in a KB-Vin 10 cells. Proceeding of AACR,
2005.
14. Chang JY, Liu TW, Pan WY, Liu JF, Kuo CC, Yang YN, Chen LT and Chen SA. Synergistc
cytotoxicity of arsenic trioxide and BCNU in human cancer cells and its mechanism of
interaction. Joint meeting of Chinese Oncology Society, 2005.
15. Chang JY, Chen LT and Chang CY. DB67, a novel topoisomerase I inhibitor, synergize with
cisplatin to induce protein-linked DNA breaks in human cancer cells. Joint Meeting of
Chinese Oncology Society, 2005.
16. Shiah HS, Lee WS, Juang SH, Chang CJ, Chang JY. Induction of cell death by a novel
selenophene derivative, D-501036, in human cancer cells. Clinical Cancer Research 11(24)
part 2, 9101s, 2005.
17. Chen LT, Chen CC, Tsou TC, Pan WY, Kuo CC, Liu JF, Yeh SC, Tsai FY, Hsieh HP, Chang
JY*. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell
line with enhanced sensitivity to 5-FU. Proceeding of EORTC-NCI-AACR , 59, 2006.
18. Lung CC ,Juang SH, Hsu PC, Hseu KS, Shiah HS, Li YC, Kuo CC, Chang CJ, and Chang
JY*. D-501036, a Novel Selenophene-based Triheterocycle Derivative, Exhibits Potent in
vitro and in vivo Anti-tumoral Activity Which Involves DNA damage and ATM activation.
14
17/05/03
Proceeding of EORTC-NCI-AACR , 92, 2006.
19. Kuo CC, Liu JF, and Chang JY*. Tamoxifen accelerates proteosomal degradation of
O6-methylguanine DNA methytransferase in human cancer cells. Proceeding of
EORTC-NCI-AACR , 155, 2006.
20. Chang JY and Liu JP. A novel oral indoline-sulfonamide derivative, J30, exhibits potent
activity against human cancer cells both in in vitro and in vivo through disruption of
microtubule. 6th AFMC International Medicinal Chemistry Symposium, 2007 (invited
speech).
21. Reddy, G.R., Liou, J.-P., Chang, C.-Y., Kuo, C.-C., Chang, J.-Y., Hsieh, H.-P. Synthesis and
structure-activity relationships of aroyl naphthophenones as anti-tubulin agents. Annual
Chinese Chemical Society & ICCT 2007 Joint Conference. Hsinchu (Taiwan). Dec 12~16,
2007.
22. Kuo, C.-C., Liu, J.-F., Shiah, H.-S., Ma, L.-C., Chang, J.-Y. Tamoxifen accelerates
ubiquitin-dependent proteasomal degradation of O6-methylguanine DNA methyltransferase
in human cancer cells. The 12th Joint Congress of Oncology Societies of Taiwan. Abstract
#A-I-1. Taipei (Taiwan). May 6~7, 2007. (Award of the Best Research Project)
23. Kao, Y.-H., Hsieh, H.-P., Kumar, S., Pan, W.-Y., Kuo, C.-C., Hsu, K.-S., Chang, C.-Y., Liu,
J.-F., Chuang, S.-E., Chang, J.-Y. BPR1H0101, a novel synthetic peroxisome
proliferators-activated receptor / (PPAR /) agonist, inhibits topoisomerase II catalytic
activity. The 12th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-2. Taipei
(Taiwan). May 6~7, 2007.
24. Yeh TK, Li CM, Chen CP, Huang CL, Wang HS, Shen CJ, Chang CY, Chang, CM, Chao YS,
Lin CT, Chang JY, and Chen CT. Comparative Antitumor Activities and Pharmacokinetics
of Silatecans DB-67 and DB-91. Joint Meeting of Chinese Oncology Society, 2008.
25. Hsieh CC, Kuo YS, Kuo CC, Chang CY, Chien SC, and Chang JY. Chamacypanone C, a
Novel Skeleton Microtubule Inhibitor with Antimitotic Activity in Human Tumor Cells.
Joint Meeting of Chinese Oncology Society, 2008,
26. Chen LT, Chang TC, Cheng AL, Yang CH, Shiah HS, Chang JY, Yeh CG. Phase I study of
liposome encapsulated irinotecan (PEP02) in advanced solid tumor patients. ASCO
proceeding, # 2565, 2008.
27. Chen LT, Shiah HS, Chen C, Lin Y, Lin P, Su W and Chang JY. Randomized, phase I and
PK study of RAD001, a mTOR inhibitor, in patients with advanced HCC. ASCO GI
meeting. 2009
28. Cheung, C.-H. A., Kuo, C.-C., Chen, H.-H., Chang, C.-Y., Coumar, M.S. Hsieh, H.-P.,
Chang, J.-Y. Down-regulation of survivin enhances sensitivity to BPR0L075 in human
cancer cells via caspase-independent mechanisms. The 14th Joint Congress of Oncology
Societies of Taiwan. Abstract #A-I-21. Taipei (Taiwan). May 2~3, 2009.
29. Liu, K.-J., Kuo, C.-C., Hong, Y.-M., Yang, Lai, W.-Y., Lin, C.-C., Chang, M. D.-T., Lyu,
P.-C., Uang, B.-J., Chang, J.-Y. A novel -ketone amide compound CCL-ymc-7K with
inhibitory activity on cathepsin S displays anti-angiogenesis potential. The 14th Joint
15
17/05/03
Congress of Oncology Societies of Taiwan. Abstract #A-I-23. Taipei (Taiwan). May 2~3,
2009.
30. Chen, J.-J., Lin, C.-C., Wang, X.-J., Lin, S.-J., Chang, D.-T., Lin, S.-C., Chiang, G.-H.,
Lee, P.-Y., Chang, W.-S., Kuo, C.-C., Liu, K.-J., Chang, J.-Y. Synthesis
-ketone amides
as cathepsin S inhibitors. The 14th Joint Congress of Oncology Societies of Taiwan.
Abstract #A-I-39. Taipei (Taiwan). May 2~3, 2009.
31. Lu, H.-J., Uang, B.-J., Liu, K.-J., Kuo, C.-C., Chang, Chang, W.-S., Chang, J.-Y.
Discovery of potent inhibitors for cathepain S. The 14th Joint Congress of Oncology
Societies of Taiwan. Abstract #A-I-42. Taipei (Taiwan). May 2~3, 2009.
32. Liu, K.-J., Chang, W.-S., Kuo, C.-C., Hong, Y.-M., Yang, Y.-N., Liu, H.-J., Uang, B.-J.,
Chang, J.-Y. HJL-kpw-2py-03, a novel p38 MAPK inhibitor derivative with potent
anti-angiogenic and anti-metastatic activities against human malignancies. The 14th Joint
Congress of Oncology Societies of Taiwan. Abstract #A-I-45. Taipei (Taiwan). May 2~3,
2009.
33. Chiang, G.-H., Lin, S.-C., Lee, P.-Y., Chen, J.-J., Lin, C.-C., Kuo, C.-C., Liu, K.-J.,
Chang, J.-Y., Chang, M. D.-T., Uang, B.-J., Chang, W.-S. CCL-ymc-7K, a newly
synthesized -ketone amide compound, serves as a direct inhibitor of Cathepsin S
protease to reduce tumor cell migration and invasion. The 14th Joint Congress of
Oncology Societies of Taiwan. Abstract #A-I-59. Taipei (Taiwan). May 2~3, 2009.
34. Lin, S.-C., Chiang, G.-H., Lee, P.-Y., Chen, J.-J., Lin, C.-C., Kuo, C.-C., Liu, K.-J.,
Chang, J.-Y., Chang, M. D.-T., Uang, B.-J., Chang, W.-S. Study of the anti-migratory and
anti-invasive effects of newly synthesized inhibitors of cancer-related cathepsin S
protease. The 14th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-62.
Taipei (Taiwan). May 2~3, 2009.
35. Cheung, C.-H.A., Chang, C.-Y., Hsieh, H.-P., Chang, J.-Y. Down-regulation of survivin
enhances sensitivity to BPR0L075 in human cancer cells via caspase-independent
mechanisms. American Association for Cancer Research 100th Annual Meeting.
Abstract # 5542. Denver (USA). April 18~22, 2009.
36. Hsieh, C.-C., Kuo, Y.-H., Kuo, C.-C., Chang, C.-Y., Chien, S.-C., Chang, J.-Y.
Chamacypanone C, a novel skeleton microtubule inhibitor with antimitotic activity in
human tumor cells. The 13th Joint Congress of Oncology Societies of Taiwan. Abstract
#A-I-18. Taipei (Taiwan). May 3~4, 2008. (Award of the Best Research Project)
37. Kao, Y.-H., Hsieh, H.-P., Kumar, S., Pan, W.-Y., Kuo, C.-C., Hsu, K.-S., Chang, C.-Y., Liu,
J.-F., Chuang, S.-E., Chang, J.-Y. A novel peroxisome proliferators-activated receptor
/ agonist, BPR1H0101, inhibits DNA topoisomerase II catalytic activity in human
cancer cells. The 13th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-19.
Taipei (Taiwan). May 3~4, 2008. (Award of the Best Research Project)
38. Yun-Ching Cheng, Wen-Yang Lai, Chi-Yen Chang, Wen-Yu Pan, Jing-Ping Liou,
Ching-Chuan Kuo, Jang-Yang Chang. MPT0B098, a novel microtubule-destabilizing
16
17/05/03
agent, displays anti-angiogenic potential via AKT/p70S6K/HIF-1/VEGF signaling
in lung cancers. Proceeding of APCC, #P-50, 2009.( Young Investigators Award)
39. Chi-Yen Chang, Chia-Chi Lung, Yueh-Hsiung Kuo, Ching-Chuan Kuo, Kuo-Shun
Hsu,Kai-Hsi Lu, Chi-Hung Lin, Jang-Yang Chang.YS-5, A novel neolignan induces
apoptosis cell death via activated spindle assembly checkpoint in human cancer cells.
Proceeding of APCC, #P-74, 2009.
40. Chun Hei Antonio Cheung, Su-Ying Wu, Chi-Yen Chang, Hsing-Pang
Hsieh, Jang-Yang Chang. Class I β-tubulin mutations induce resistance to
microtubule destabilizer through stabilization of the microtubule networks.
AACR 101st meeting. Abstract No. 2555. 2010.
41 Chun Hei Antonio Cheung, Huang-Hui Chen, Li-Ting Cheng, Kevin W. Lyu, Jagat R.
42.
43.
Kanwar, Jang-Yang Chang. Targeting Hsp90 with small molecule inhibitors induces the
overexpression of the anti-apoptotic molecule, survivin, in human cancer cells. AACR
101st meeting. Abstract No. 4447. 2010.
Kwang-Yu Chang, Jang-Yang Chang. Novel PI3K/mTOR dual inhibitor, NVP-BGT226,
displays potent inhibitory activity against human head and neck cancer cell growth in
vitro and in vivo. AACR 101st meeting. Abstract No. 4471., 2010.
Fan-Yu He, Jang-Yang Chang, Ching-Chuan Kuo, Wen-Yu Pan, Li-Tzong Chen,
Wen-Hui Weng. microRNA expression patterns associated with resistance to
platinum-based chemotherapy in human cancer cell lines. AACR 101st meeting. Abstract
No. 2045., 2010.
44. Chang, J.-Y. Cathepsin S: a potential target for anticancer drug discovery. Invited speaker
at Lecture 26. The 15th Joint Congress of Oncology Societies of Taiwan. Abstract
#A-I-12. Taipei (Taiwan). May 1~2, 2010.
45. Kuo, C.-C., Liu, T.-W., Chen, L.-T., Shiah, H.-S., Pan, W.-Y., Liu, J.-F., Cheng, Y.-T.,
Chang, J.-Y. Synergistic augmentation of arsenic trioxide–induced cytotoxicity by
BCNU through reactive oxygen species-related autophagic pathway in human solid
tumors. The 15th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-14.
Taipei (Taiwan). May 1~2, 2010.
46. Chen, H.-H., Cheng, Y.-T., Lai, W.-Y., Chang, J.-Y., Kuo, C.-C. Development of
Etoposide-driven Drug Resistance through NRF2/ABCC1 Axis in Human Oral
Malignancies. The 15th Joint Congress of Oncology Societies of Taiwan. Abstract
#A-I-16. Taipei (Taiwan). May 1~2, 2010.
Book:
1. 吳秋文等主編: 胃癌的診斷與治療：胃癌之輔助化學治療。Pp 419-426
Patents:
1. Etoposide analogs. US 5332811
2. Cheng CT and Chang JY. TW0228417B, 2002/9/27-2022/9/26, NHRI
3. Su TL, Chou TC and Chang JY. 5-(9-Acridinylamino)-Toluidine Compounds. US6821983B2;
17
17/05/03
2003/7/30-2023/7/29; Academia Sinica (NSC90-2320-B-001-032)
4. Su TL, Chou TC and Chang JY. 5-(9-Acridinylamino)-Toluidine Compounds. ROC 1-246508.
2006 1/1- 2023 12/13; Academia Sinica; (NSC90-2320-B-001-032)
5. Hsieh HP, Liou JP, Chang JY, Chang CW. Indole Compounds. US6933316
(2002.12.12~2022.12.12); NHRI
6. Hsieh HP, Liou JP, Chang JY, Chang CW. Indole Compounds. CA2437104, August 13, 2003.
7. Hsieh HP, Liou JP, Chang JY, Chang CW. Indole Compounds as inhibitors of tubulin
polymerization for the treatment of angiogenesis-related disorders.EP1506960, August 7,
2003.
8. Hsieh HP, Liou JP, Chang JY, Chang CW. Indole Compounds. US2005/0267108, August 1,
2005.
9. Hsieh HP, Liou JP, Chang JY, Chang CW. Indole Compounds. US2005/0267194, August 1,
2005.
10. Hsieh HP, Tung YS, Liou JP, Chang JY, Chao, YS. Anti-Tumor Compounds. USA 7456289
B2 Nov 25, 2008.
11. Hsieh HP, Tung YS, Liou JP, Chang JY, Chao, YS. Anti-Tumor Compounds.
WO2006/074041, Dec. 28, 2005.
12. Hsieh HP, Liou JP, Chang JY, Chang CW，吲哚化合物，中華民國 TW2003/01110, Dec. 13,
2001.
13. Hsieh HP, Tung YS, Liou JP, Chang JY, Chao, YS，抗腫瘤化合物，中華民國 TW2006/21230,
Dec. 28, 2005.
14. Liou JP, Chang JY, Hsieh HP. Indoline-Sulfonamides Compounds. 中華民國 Aug. 31,
2006.
18
17/05/03